Mutant CALR’s “sweet tooth”
Open Access
- 15 September 2022
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 140 (11) , 1187-1189
Abstract
In this issue of Blood, Jutzi et al1 present compelling evidence of glycosylation as a potential therapeutic vulnerability in calreticulin (CALR)-mutated myelopKeywords
This publication has 10 references indexed in Scilit:
- Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNsBlood, 2022
- Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic LandscapeCancer Research, 2022
- Mutant calreticulin in myeloproliferative neoplasmsBlood, 2019
- Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPNBlood, 2018
- Myeloproliferative NeoplasmsNew England Journal of Medicine, 2017
- Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic TransformationCancer Discovery, 2016
- SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2New England Journal of Medicine, 2013
- Somatic Mutations of Calreticulin in Myeloproliferative NeoplasmsNew England Journal of Medicine, 2013
- A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2012
- Extracellular Domain N-Glycosylation Controls Human Thrombopoietin Receptor Cell Surface LevelsFrontiers in Endocrinology, 2011